Improving kidney transplant success using gene therapy techniques.
Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectors
This study is exploring a new way to make kidney transplants work better by using a special treatment on donor kidneys before they are transplanted, which could help them last longer and function more effectively for patients receiving them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11081713 on NIH RePORTER |
What this research studies
This research investigates a novel method to enhance kidney transplant outcomes by using gene therapy delivered through a specialized organ perfusion system. The approach aims to directly treat donor kidneys before transplantation, potentially improving their function and longevity. By utilizing adeno-associated viral vectors, the study seeks to reduce the immune response against the transplanted organ, which is a major cause of graft failure. The research will be conducted using a non-human primate model to ensure the safety and effectiveness of this technique before moving to human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with end-stage renal disease who are awaiting kidney transplantation.
Not a fit: Patients who are not candidates for kidney transplantation or those with acute kidney injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the longevity and function of kidney transplants, benefiting patients with end-stage renal disease.
How similar studies have performed: Other research has shown promise in using gene therapy for organ transplants, but this specific approach using ex vivo perfusion is relatively novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Barbas, Andrew Serghios — Duke University
- Study coordinator: Barbas, Andrew Serghios
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.